Surgical oncologist Mr Myles Smith and colleagues recently published a new article in the International Journal of Experimental and Clinical Chemotherapy entitled ‘KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment’.
Gastrointestinal Stromal Tumours (GISTs) are the commonest sarcoma of the gastrointestinal tract. They usually occur mainly in the stomach and then the small bowel. KIT exon 9-mutant GISTs represent a subtype of GIST distinct from other GISTs, including the more common KIT exon 11-mutant GISTs.
Here, Mr Smith and his colleagues review the unique and often poorly recognised molecular, biological and clinical characteristics that differentiate KIT exon 9-mutant GISTs from other GIST subtypes.
A better understanding of the molecular biology and clinical behaviour of KIT exon 9-mutant GISTs may help identify more improved treatment options.
You can read the published study here.